Genetics Generation Advancement Corp
Genetics Generation Advancement Corp is a biotechnology company engaged in pharmaceuticals and medical research, primarily generating revenue through product sales and research activities.
Business. Genetics Generation Advancement Corp (4160.TWO) is a biotechnology and medical research company operating within the healthcare sector. The firm is listed on the Taiwan Premium Exchange (TPEx). Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Genetics Generation Advancement Corp (4160.TWO) is a biotechnology and medical research company operating within the healthcare sector. The firm is listed on the Taiwan Premium Exchange (TPEx). Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Genetics Generation Advancement Corp maintains a strong liquidity position, with a current ratio of 3.62, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's cash and equivalents amount to 129,986,000 TWD, which is a significant portion of its total assets, further supporting its liquidity. The debt-to-equity ratio is 0.04, suggesting a conservative capital structure with minimal reliance on debt financing.
In terms of profitability, the company's return on equity (ROE) is 3.1%, and its return on assets (ROA) is 2.4%. These figures are below the industry median for ROE and ROA, indicating that the company is not generating returns as efficiently as its peers. The net income of 14,219,000 TWD and operating income of 13,050,000 TWD reflect modest profitability, with a gross profit margin of 40.0%.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risk if demand in its primary market fluctuates.
Looking at the growth trajectory, the company's revenue for the latest period is 166,874,000 TWD, with a gross profit of 66,757,000 TWD. While the company has a positive operating cash flow of 14,029,000 TWD, the capital expenditure of -281,000 TWD indicates minimal investment in new assets. Analyst estimates suggest a recent actual revenue of 266,868,000 TWD, which is higher than the reported revenue, indicating potential growth in the near term.
The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and high cash reserves support the low liquidity risk rating. Additionally, the absence of dilution sources and the stable share count suggest that the company is not currently under pressure to issue new shares.
Recent events, as reflected in the financial data, show a negative EPS of -0.80 TWD, which may indicate challenges in profitability despite the positive net income. The discrepancy between the reported revenue and the analyst estimate suggests potential volatility or uncertainty in the company's financial performance.
- The company has a strong liquidity position with a current ratio of 3.62 and significant cash reserves.
- Profitability metrics such as ROE and ROA are below industry medians, indicating inefficiency in generating returns.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company has low liquidity and dilution risks, supported by a conservative capital structure and no immediate filing-based flags.
- Analyst estimates suggest potential revenue growth, but the negative EPS indicates challenges in profitability.
Bull / Bear case
Generated · model-assistedOperating income surged 166.6% year-over-year, demonstrating significant operational leverage and improved profitability compared to the prior fiscal period.
Net income grew at a 26.5% compound annual growth rate over four years, indicating consistent long-term earnings expansion.
Low dilution, liquidity, and credit risk flags suggest a stable financial structure with minimal immediate balance sheet threats.
Free cash flow turned negative at -33.8 million TWD in FY0, reversing the positive trend seen in previous years.
Long-term debt increased substantially to 79.2 million TWD in FY0, rising from 40.3 million TWD in the prior year.
Revenue growth slowed to a 2.4% compound annual growth rate over four years, suggesting limited top-line expansion momentum.
Return on assets of 2.4% remains modest, indicating that asset utilization efficiency has not dramatically improved despite profit growth.
Debt-to-equity ratio of 0.04 is below the cohort median, but rising debt levels warrant monitoring for future leverage increases.
In focus — financials by report
Revenue TWD 143.4M, −14,1% YoY; Operating income −47,0% YoY.
- ▍Revenue TWD 143.4M, −14,1% YoY
- ▍Operating income −47,0% YoY
- ▍Net income −46,2% YoY
- ▍Free cash flow −44,4% YoY
- ▍Net margin 5.3%
Revenue TWD 155.2M; Operating income TWD 622.0k.
- ▍Revenue TWD 155.2M
- ▍Operating income TWD 622.0k
- ▍Net margin 2.0%
Revenue TWD 603.1M, −8,9% YoY; Operating income −76,1% YoY.
- ▍Revenue TWD 603.1M, −8,9% YoY
- ▍Operating income −76,1% YoY
- ▍Net income −60,9% YoY
- ▍Free cash flow −199,2% YoY
- ▍Net margin 3.5%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Genetics Generation Advancement Corp Market data — financials · 2026-05-26
- Genetics Generation Advancement Corp Market data — analyst estimates · 2026-05-26